Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
Oruka Therapeutics (Nasdaq: ORKA), a clinical-stage biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in the upcoming Jefferies Global Health Care Conference. The presentation is scheduled for Wednesday, June 4th, 2025, at 12:50 PM ET in New York. Investors and interested parties can access the presentation webcast and replay through Oruka's investor events website at ir.orukatx.com.
Oruka Therapeutics (Nasdaq: ORKA), una società biotecnologica in fase clinica specializzata nello sviluppo di nuovi biologici per malattie cutanee croniche come la psoriasi a placche, ha annunciato la sua partecipazione al prossimo Jefferies Global Health Care Conference. La presentazione è programmata per mercoledì 4 giugno 2025, alle 12:50 PM ET a New York. Investitori e interessati potranno seguire la presentazione in diretta streaming e rivederla sul sito dedicato agli eventi per investitori di Oruka, all'indirizzo ir.orukatx.com.
Oruka Therapeutics (Nasdaq: ORKA), una empresa biotecnológica en fase clínica enfocada en desarrollar nuevos productos biológicos para enfermedades crónicas de la piel, incluyendo la psoriasis en placas, ha anunciado su participación en la próxima Jefferies Global Health Care Conference. La presentación está programada para el miércoles 4 de junio de 2025 a las 12:50 PM ET en Nueva York. Inversionistas y personas interesadas podrán acceder a la transmisión en vivo y a la repetición de la presentación a través del sitio web de eventos para inversionistas de Oruka en ir.orukatx.com.
Oruka Therapeutics(나스닥: ORKA)는 판상 건선 등 만성 피부 질환을 위한 혁신적인 생물학적 제제 개발에 주력하는 임상 단계 바이오테크 기업으로, 다가오는 Jefferies Global Health Care Conference에 참여한다고 발표했습니다. 발표는 2025년 6월 4일 수요일 오후 12시 50분(동부 시간) 뉴욕에서 진행될 예정입니다. 투자자 및 관심 있는 분들은 Oruka의 투자자 이벤트 웹사이트 ir.orukatx.com에서 발표 웹캐스트와 다시보기를 시청할 수 있습니다.
Oruka Therapeutics (Nasdaq : ORKA), une société biotechnologique en phase clinique spécialisée dans le développement de nouveaux biologiques pour les maladies chroniques de la peau, notamment le psoriasis en plaques, a annoncé sa participation à la prochaine Jefferies Global Health Care Conference. La présentation est prévue pour le mercredi 4 juin 2025 à 12h50 ET à New York. Les investisseurs et parties intéressées pourront accéder à la diffusion en direct et au replay via le site dédié aux événements investisseurs d’Oruka à l’adresse ir.orukatx.com.
Oruka Therapeutics (Nasdaq: ORKA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Biologika für chronische Hauterkrankungen wie Plaque-Psoriasis spezialisiert hat, gab seine Teilnahme an der bevorstehenden Jefferies Global Health Care Conference bekannt. Die Präsentation ist für Mittwoch, den 4. Juni 2025, um 12:50 Uhr ET in New York geplant. Investoren und Interessierte können die Präsentation als Webcast live verfolgen und später über die Investor-Event-Website von Oruka unter ir.orukatx.com abrufen.
- None.
- None.
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Jefferies Global Health Care Conference in New York, NY:
Date: Wednesday, June 4th, 2025
Time: 12:50PM ET
A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
When is Oruka Therapeutics (ORKA) presenting at the Jefferies Healthcare Conference 2025?
What diseases is Oruka Therapeutics (ORKA) developing treatments for?
How can investors watch Oruka Therapeutics' (ORKA) Jefferies conference presentation?
What stage of development is Oruka Therapeutics (ORKA) currently in?
